Show
Sort by
-
- Conference Paper
- C3
- open access
Four- or 5-weeks of radiotherapy for prostate cancer : interim results of a randomized phase 3 trial
-
- Conference Paper
- C3
- open access
Patient-reported outcomes in the search for the optimal radiotherapy schedule for prostate cancer
-
4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial
-
Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer : a 10-years single centre experience
-
Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?
-
Reliability and accuracy assessment of radiation therapy oncology group-endorsed guidelines for brachial plexus contouring